No connection

Search Results

AMRN vs KROS

AMRN
Amarin Corporation plc
BEARISH
Price
$15.34
Market Cap
$319.1M
Sector
Healthcare
AI Confidence
85%
KROS
Keros Therapeutics, Inc.
NEUTRAL
Price
$11.21
Market Cap
$341.4M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
AMRN
--
KROS
4.87
Forward P/E
AMRN
13.11
KROS
-2.22
P/B Ratio
AMRN
0.7
KROS
0.72
P/S Ratio
AMRN
1.49
KROS
1.4
EV/EBITDA
AMRN
-557.89
KROS
-0.69

Profitability

Gross Margin
AMRN
56.57%
KROS
47.91%
Operating Margin
AMRN
-4.59%
KROS
-7576.62%
Profit Margin
AMRN
-18.16%
KROS
35.65%
ROE
AMRN
-8.21%
KROS
19.9%
ROA
AMRN
-1.29%
KROS
9.25%

Growth

Revenue Growth
AMRN
-21.0%
KROS
-87.3%
Earnings Growth
AMRN
--
KROS
--

Financial Health

Debt/Equity
AMRN
0.02
KROS
0.06
Current Ratio
AMRN
3.34
KROS
15.45
Quick Ratio
AMRN
2.21
KROS
15.1

Dividends

Dividend Yield
AMRN
--
KROS
--
Payout Ratio
AMRN
0.0%
KROS
0.0%

AI Verdict

AMRN BEARISH

AMRN's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining revenue, and negative earnings trends. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given the company's negative ROE, ROA, and persistent losses despite a strong gross margin. While the company exhibits a low debt-to-equity ratio and high liquidity, these strengths are overshadowed by a 21% YoY revenue decline and a 94.7% Q/Q EPS drop. Analysts have issued a 'underperform' rating with a target price below current levels, reflecting skepticism about near-term sustainability. The stock's recent 87% 1-year gain is likely driven by speculative momentum rather than fundamentals.

Strengths
High gross margin of 56.57% suggests strong pricing power or cost control in production
Extremely low debt-to-equity ratio of 0.02 indicates minimal financial leverage and low default risk
Strong liquidity with current ratio of 3.34 and quick ratio of 2.21, providing buffer against short-term obligations
Risks
Piotroski F-Score of 2/9 signals severe financial weakness, with multiple red flags including negative ROE, ROA, and declining profitability
21% year-over-year revenue decline and negative earnings growth indicate deteriorating business fundamentals
No analyst consensus on forward earnings, with target price of $12.00 below current price, signaling bearish outlook
KROS NEUTRAL

KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.

Strengths
Perfect Piotroski F-Score (9/9) indicating strong short-term financial improvement
Exceptional liquidity with a Current Ratio of 15.45
Very low leverage with a Debt/Equity ratio of 0.06
Risks
Catastrophic revenue decline of -87.30% YoY
Extreme operating inefficiency with an operating margin of -7576.62%
Bearish insider sentiment with sales from CEO, CFO, and General Counsel

Compare Another Pair

AMRN vs KROS: Head-to-Head Comparison

This page compares Amarin Corporation plc (AMRN) and Keros Therapeutics, Inc. (KROS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile